[残病检测对核型正常、FLT3-ITD阴性的急性髓系白血病的预后价值]。

IF 0.4 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY
Samiha Jaddaoui, Hanaa Bencharef, Sara Addakiri, Hind Dehbi, Amal Tazzite, Mouna Lamchahab, Bouchra Oukkache
{"title":"[残病检测对核型正常、FLT3-ITD阴性的急性髓系白血病的预后价值]。","authors":"Samiha Jaddaoui,&nbsp;Hanaa Bencharef,&nbsp;Sara Addakiri,&nbsp;Hind Dehbi,&nbsp;Amal Tazzite,&nbsp;Mouna Lamchahab,&nbsp;Bouchra Oukkache","doi":"10.1684/abc.2023.1798","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Complete remission (CR) in patients with acute myeloid leukemia (AML) is still morphologicaly defined, thus corresponding to a wide range of tumor burden.</p><p><strong>Objectives: </strong>we aimed to evaluate the residual disease (MRD) status in patients with AML, as well as perform a molecular analysis of the FLT3/ITD gene in patients with normal karyotype.</p><p><strong>Material and methods: </strong>adult patients with AML, diagnosed according to the WHO 2016 criteria, were included. MRD was detected using flow cytometric techniques after induction treatment resulting in CR.</p><p><strong>Results: </strong>thirty patients met our inclusion criteria. 83 % of them had an intermediate risk status, 67 % of which (20/30) having a normal karyotype. MRD and leukemic stem cell (LSC) positivity in this group was predominant with considerable decrease in benign progenitor count. The relapse-free survival (RFS) in the group of MRD negative patients with normal cytogenetics and non-mutated FLT3 gene was better than the RFS in all of our patients studied.</p><p><strong>Conclusion: </strong>MRD and LSC are powerful prognostic factors for relapse. They should be routinely integrated to guide better management of AML.</p>","PeriodicalId":7892,"journal":{"name":"Annales de biologie clinique","volume":"81 2","pages":"136-144"},"PeriodicalIF":0.4000,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Prognostic value of residual disease detection in acute myeloid leukemia with normal karyotype and negative FLT3-ITD].\",\"authors\":\"Samiha Jaddaoui,&nbsp;Hanaa Bencharef,&nbsp;Sara Addakiri,&nbsp;Hind Dehbi,&nbsp;Amal Tazzite,&nbsp;Mouna Lamchahab,&nbsp;Bouchra Oukkache\",\"doi\":\"10.1684/abc.2023.1798\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Complete remission (CR) in patients with acute myeloid leukemia (AML) is still morphologicaly defined, thus corresponding to a wide range of tumor burden.</p><p><strong>Objectives: </strong>we aimed to evaluate the residual disease (MRD) status in patients with AML, as well as perform a molecular analysis of the FLT3/ITD gene in patients with normal karyotype.</p><p><strong>Material and methods: </strong>adult patients with AML, diagnosed according to the WHO 2016 criteria, were included. MRD was detected using flow cytometric techniques after induction treatment resulting in CR.</p><p><strong>Results: </strong>thirty patients met our inclusion criteria. 83 % of them had an intermediate risk status, 67 % of which (20/30) having a normal karyotype. MRD and leukemic stem cell (LSC) positivity in this group was predominant with considerable decrease in benign progenitor count. The relapse-free survival (RFS) in the group of MRD negative patients with normal cytogenetics and non-mutated FLT3 gene was better than the RFS in all of our patients studied.</p><p><strong>Conclusion: </strong>MRD and LSC are powerful prognostic factors for relapse. They should be routinely integrated to guide better management of AML.</p>\",\"PeriodicalId\":7892,\"journal\":{\"name\":\"Annales de biologie clinique\",\"volume\":\"81 2\",\"pages\":\"136-144\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales de biologie clinique\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1684/abc.2023.1798\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1684/abc.2023.1798","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

急性髓系白血病(AML)患者的完全缓解(CR)仍然是形态学定义的,因此对应于广泛的肿瘤负荷。目的:我们旨在评估AML患者的残留疾病(MRD)状态,并对正常核型患者的FLT3/ITD基因进行分子分析。材料和方法:纳入根据WHO 2016标准诊断的成年AML患者。诱导治疗后,流式细胞术检测MRD。结果:30例患者符合我们的纳入标准。其中83%的人处于中等风险状态,67%(20/30)的人核型正常。该组以MRD和白血病干细胞(LSC)阳性为主,良性祖细胞计数明显减少。细胞遗传学正常且FLT3基因未突变的MRD阴性患者的无复发生存期(RFS)优于我们研究的所有患者的RFS。结论:MRD和LSC是预测复发的重要因素。它们应定期整合,以指导更好地管理“反洗钱”。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Prognostic value of residual disease detection in acute myeloid leukemia with normal karyotype and negative FLT3-ITD].

Introduction: Complete remission (CR) in patients with acute myeloid leukemia (AML) is still morphologicaly defined, thus corresponding to a wide range of tumor burden.

Objectives: we aimed to evaluate the residual disease (MRD) status in patients with AML, as well as perform a molecular analysis of the FLT3/ITD gene in patients with normal karyotype.

Material and methods: adult patients with AML, diagnosed according to the WHO 2016 criteria, were included. MRD was detected using flow cytometric techniques after induction treatment resulting in CR.

Results: thirty patients met our inclusion criteria. 83 % of them had an intermediate risk status, 67 % of which (20/30) having a normal karyotype. MRD and leukemic stem cell (LSC) positivity in this group was predominant with considerable decrease in benign progenitor count. The relapse-free survival (RFS) in the group of MRD negative patients with normal cytogenetics and non-mutated FLT3 gene was better than the RFS in all of our patients studied.

Conclusion: MRD and LSC are powerful prognostic factors for relapse. They should be routinely integrated to guide better management of AML.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annales de biologie clinique
Annales de biologie clinique 医学-医学:研究与实验
CiteScore
0.80
自引率
20.00%
发文量
53
审稿时长
6-12 weeks
期刊介绍: Multidisciplinary information with direct relevance to everyday practice Annales de Biologie Clinique, the official journal of the French Society of Clinical Biology (SFBC), supports biologists in areas including continuing education, laboratory accreditation and technique validation. With original articles, abstracts and accounts of everyday practice, the journal provides details of advances in knowledge, techniques and equipment, as well as a forum for discussion open to the entire community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信